ATNAA atropine and pralidoxime chloride
These highlights do not include all the information needed to use ATNAA safely and effectively. See full prescribing information for ATNAA. ATNAA (atropine and pralidoxime chloride injection), for intramuscular use Initial U.S. Approval: 2002
Approved
Approval ID
596c7a8f-27cd-4de2-9491-476f43570b8b
Product Type
HUMAN PRESCRIPTION DRUG LABEL
Effective Date
Jul 18, 2022
Manufacturers
FDA
Meridian Medical Technologies, LLC
DUNS: 049504624
Products 1
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
atropine and pralidoxime chloride
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
NDC Product Code11704-777
Application NumberNDA021175
Product Classification
M
Marketing Category
C73594
G
Generic Name
atropine and pralidoxime chloride
Product Specifications
Route of AdministrationINTRAMUSCULAR
Effective DateMay 25, 2022
FDA Product Classification